Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, which develops in the lungs and can cause symptoms like persistent cough, chest pain, and difficulty breathing.
Durvalumab for Non-Surgical Non-Small Cell Lung Cancer
We are studying the safety and effectiveness of the immunotherapy durvalumab followed by radiation in patients with early stage or locally advanced non-small cell lung cancer. This trial aims to find out if this treatment approach can help those who cannot have surgery.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a history of lung cancer (NSCLC)?
- Are you currently pregnant or breastfeeding?
- Are you taking any immunosuppressive medications like prednisone or other steroids?
- Have you had any major surgery in the last 28 days?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
Medical Management
Paranhos, Portugal
Sponsor: Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.